

AccuVert™ HIV-1 Seroconversion Panel 0600-0265 (PRB960)

INTENDED USE

The AccuVert™ HIV-1 Seroconversion Panel 0600-0265 (PRB960) is intended for use by diagnostics manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HIV-1 test methods. Characterized specimens and comprehensive data are provided for comparative analysis. For Research Use Only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product is a 9-member HIV-1 seroconversion panel. Panel members represent serial bleeds from a single plasma donor collected during the development and progression of an HIV infection. Panel members consist of undiluted, naturally occurring plasma samples. Each sample represents a single collection event. All units were maintained in a frozen state, except for the interval of dispensing into vials. No preservatives were added.

Material Number: 0600-0265, 1 vial per member
9 members, 1.0 mL per vial

STORAGE

Panel members should be stored frozen at -65°C to -80°C to preserve HIV-1 RNA. HIV antibody and antigen will be preserved at -10°C or colder. LGC SeraCare recommends that the panel members be divided into smaller aliquots, as appropriate, for ease in repeated testing and to avoid multiple freeze-thaw cycles. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The data sheet for AccuVert HIV-1 Seroconversion Panel 0600-0265 (PRB960) is available at www.seracare.com. The data sheet lists results for panel members generated using commercially available screening and confirmatory tests. Tests were performed at LGC SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these test procedures. Information regarding specific test methods is available on the data sheet. Data Sheets are updated when new data are available.

LIMITATIONS

This Panel is offered for research use only. Not for use in diagnostic procedures. The data are provided for informational purposes only. LGC SeraCare does not claim that others can duplicate these results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Panel members were tested and some were found positive by tests for HIV markers including HIV-1 RNA, HIV-1 antigen and anti-HIV. Panel members were tested and some were found positive for HCV RNA.

The units that make up this panel were tested and found negative for anti-HCV, HBsAg, and HBV DNA. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

**For assistance, contact LGC SeraCare at
508.244.6400.**

The package insert for this panel can be found at
www.seracare.com.

A printed copy of the package insert or data sheet may be requested by email at CDx-Info@LGCGroup.com or by phone at 508.244.6400.